Antibiotics Technologies and Markets, 2025
12 janv. 2021 04h38 HE
|
Research and Markets
Dublin, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The "Antibiotics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for antibiotics should...
Global Antibiotic Resistance Markets to 2024: Examine 6 Key Opportunity Areas
01 oct. 2020 04h09 HE
|
Research and Markets
Dublin, Oct. 01, 2020 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics By Pathogen and Therapy Type 2020 To 2024" report has been added to ResearchAndMarkets.com's offering. ...
Global Antibiotic Resistance Markets Report 2020: Analysis and Forecasts 2017-2019 & 2020-2023 with Profiles of 100+ Companies
30 sept. 2020 04h29 HE
|
Research and Markets
Dublin, Sept. 30, 2020 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics By Pathogen and Therapy Type With Situation Analysis, Executive & Investor Guides & Customization...
FDA Grants HelixBind Breakthrough Device Designation for RaPID Sepsis Test
24 août 2020 11h47 HE
|
HelixBind
BOXBOROUGH, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
Professor Gordon Dougan Receives the 2020 Albert B. Sabin Gold Medal
13 août 2020 10h00 HE
|
The Sabin Vaccine Institute
Washington, D.C., Aug. 13, 2020 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) today announced that it has awarded its annual Albert B. Sabin Gold Medal to Gordon Dougan, FRS, professor in...
HelixBind Awarded $3MM Grant from NIH for New Rapid Test for the Early Detection of Lyme Disease
16 juil. 2020 12h01 HE
|
HelixBind
BOXBOROUGH, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for patients afflicted with invasive microbial infections,...
HelixBind Awarded $3MM Grant from NIH and Expands Clinical Advisory Board to Accelerate Development of Its Diagnostic Platform for Invasive Infections
10 juin 2020 10h29 HE
|
HelixBind
BOXBOROUGH, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
Phase Genomics Receives $1.5MM NIH Grant to Develop Fast and Affordable Commercial Antimicrobial Resistance Tracking Kit
08 janv. 2020 09h30 HE
|
Phase Genomics
SEATTLE, Washington, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Phase Genomics, Inc., the biotech leader providing proximity-ligation next-generation sequencing (NGS) solutions for metagenome assembly, today...
Allecra Therapeutics to Present Data at ASM/ESCMID 2019 Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
03 sept. 2019 07h00 HE
|
Allecra Therapeutics GmbH
LÖRRACH, Germany and SAINT-LOUIS, France, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Allecra Therapeutics (Private), a biopharmaceutical company focused on developing and commercializing novel...
BioAegis Therapeutics Reports Favorable Safety and Pharmacokinetic Results in its Phase 1b/2a Dose-Escalation Study of Recombinant Human Plasma Gelsolin with Highest Doses Ever Administered to Patients
07 août 2019 10h00 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc. announced the major findings from its Phase 1b/2a study of Recombinant Human Plasma Gelsolin for patients requiring...